Bristol-Myers Squibb Co.

NYSE:BMY  
64.86
-0.18 (-0.28%)
4:23:20 PM EDT: $64.81 -0.05 (-0.08%)
Products

U.S. FDA Accepts For Priority Review Bristol Myers Squibb And Bluebird Bio Application For Anti-BCMA Car T Cell Therapy Idecabtagene Vicleucel

Published: 09/22/2020 11:36 GMT
Bristol-Myers Squibb Co. (BMY) - U.S. Food and Drug Administration (fda) Accepts for Priority Review Bristol Myers Squibb and Bluebird Bio Application for Anti-bcma Car T Cell Therapy Idecabtagene Vicleucel (ide-cel, Bb2121).
Bristol-myers Squibb Co - FDA Set a Target Action Date of March 27, 2021.
Bristol-myers Squibb Co - Bla is Based on Results From Pivotal Phase 2 Karmma Study.